The pollution problem of pharmaceutical intermediate companies is prominent, all departments need to work together

The pollution problem of pharmaceutical intermediate companies is prominent, all departments need to work together

According to the unified deployment of the Ministry of Environmental Protection, on February 15th, the 18 inspection teams that carried out the special inspection of air quality in the first quarter of 2017 have all settled in 18 cities in Beijing, Tianjin, Hebei and surrounding areas. At present, the main problems discovered by the special supervision team of the Ministry of Environmental Protection include the inadequate pressure transmission in Shijiazhuang City, and the county-level government is still dominated by the environmental protection bureau in implementing the emergency plan for heavy pollution weather, and the participation of other departments is not high. The pollution of small and medium-sized enterprises producing pharmaceutical intermediates in Shijiazhuang is relatively serious.

Disorderly competition in the industry is becoming increasingly fierce

The so-called pharmaceutical intermediates are actually some chemical raw materials or chemical products used in the process of drug synthesis. This kind of chemical product does not require a drug production license and can be produced in a common chemical plant. As long as it reaches a certain level, it can be used for the synthesis of drugs.

It is understood that after years of development, the chemical raw materials and intermediates required for pharmaceutical production in my country can basically be matched, and only a small part need to be imported. Moreover, due to my country’s abundant resources and low raw material prices, many intermediates have been exported in large quantities.

Looking at the entire industry, most of the pharmaceutical intermediate manufacturers in my country are currently private enterprises with flexible operations and small investment scale. With the country’s increasing attention to environmental protection issues, the pressure on manufacturers to build environmental protection treatment facilities has increased, forcing companies to Only by continuously developing new products or continuously improving the production process can we maintain high production profits.

Furthermore, since the production profit of pharmaceutical intermediates is higher than that of chemical products, and the production processes of the two are basically the same, more and more small chemical companies have joined the ranks of producing pharmaceutical intermediates, resulting in increasingly disorderly competition in the industry. fierce. In the face of profit, many manufacturers bury “green”, which has also caused a lot of industrial pollution.

Faced with environmental pressure

All departments need to work together

According to Xue Xinli, director of the Tianjin Development and Reform Commission, continuous strengthening of air pollution control cooperation in the three places, unified implementation of regional heavy-polluted weather warning standards, strengthening of environmental law enforcement and emergency response, joint environmental law enforcement supervision and inspection, and coordinated investigation and punishment of cross-border environmental violations will be Current goals.

Relevant departments should fully cooperate with the progress of pollution control. Small and medium-sized pharmaceutical intermediates, as a part of the pollution source, must also fully cooperate with environmental law enforcement agencies to pay attention to pollution problems, put down the immediate interests and take the path of sustainable development.

The pharmaceutical industry is not only a high-risk, high-investment, high-tech, and high-return industry, but also an industry with heavy environmental protection, energy conservation, and emission reduction tasks in my country. Since the beginning of the 21st century, my country’s pharmaceutical industry has maintained a relatively rapid development speed. In the face of environmental protection pressure, what pharmaceutical companies need is to upgrade environmental protection technology and follow the concept of green production, rather than blindly engage in production and avoid environmental protection principles.